Rising Prevalence Of Prostate Cancer Fueling The Growth Of The Market Due To Aging Population And Increasing Case Numbers Is Supporting Development Across The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market
The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Increase In Market Value Is Predicted For The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market During The 2026–2030 Period?
The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market size has seen strong growth in recent years. It is forecast to increase from $8.43 billion in 2025 to $8.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.8%. Historically, this growth has been driven by factors such as the prevalence of prostate cancer, resistance to hormone therapy, advancements in oncology drug innovation, the availability of hospital-based cancer care, and the demographic shift towards an aging male population.
The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market is set to experience significant expansion over the next few years. It is forecast to increase to $11.04 billion in 2030, achieving a compound annual growth rate (CAGR) of 5.5%. This projected growth is driven by advancements such as biomarker-driven treatment, sophisticated targeted therapies, the uptake of oral oncology solutions, an expanding oncology pipeline, and individualized cancer care. Notable trends anticipated during this period encompass the increasing deployment of androgen receptor inhibitors, the rise of PARP inhibitor therapies, the broadening of combination treatment regimens, a greater emphasis on precision oncology, and a move towards oral oncology medications.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24495&type=smp
Which Strategic Drivers Are Supporting The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Development?
The increasing occurrence of prostate cancer is projected to fuel the expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market moving ahead. Prostate cancer is defined as a malignancy that forms within the prostate gland, which is a small male gland situated beneath the bladder and anterior to the rectum. The growing incidence of prostate cancer stems from an aging demographic, given that the likelihood of developing this cancer substantially increases with advancing age. Therapies for castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) are instrumental in managing prostate cancer by addressing later stages of the illness that have become unresponsive to standard hormone treatment. These treatments improve patient results by decelerating the progression of the disease and alleviating symptoms, consequently improving the overall quality of life. As an illustration, in October 2025, data from NHS Digital, a UK-based government agency focused on healthcare statistics, indicated 58,137 new prostate cancer diagnoses in England during 2023, marking a 6 percent rise from 2022. Consequently, the escalating prevalence of prostate cancer is stimulating the expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market.
How Does Segment Analysis Break Down The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Structure?
The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market covered in this report is segmented –
1) By Therapy Type: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy
2) By Route Of Administration: Oral, Injectable, Intravenous
3) By End User: Hospitals, Oncology Centers, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors, Androgen Synthesis Inhibitors, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists, Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists
2) By Chemotherapy: Taxanes, Platinum-Based Agents, Other Chemotherapies
3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines
4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors, Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors, Tyrosine Kinase Inhibitors (TKIs), Deoxyribonucleic Acid Damage Response (DDR) Inhibitors
5) By Radiation Therapy: External Beam Radiation Therapy, Brachytherapy, Radiopharmaceuticals
What Trends Are Influencing The Future Of The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
Leading companies in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market are concentrating on developing innovative products and securing approvals, such as dual-action tablets, to enhance treatment efficacy and patient outcomes. Dual-action tablets represent advanced formulations that combine two therapeutic agents in a single dose to simultaneously target multiple pathways in castration-resistant prostate cancer (CRPC) treatment. For instance, in August 2023, Janssen Pharmaceuticals, a Belgium-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Akeega, a novel tablet developed for the treatment of adults with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega is a precision medicine that combines a PARP inhibitor (niraparib) with a CYP17 inhibitor (abiraterone acetate), specifically targeting patients with BRCA mutations. When used alongside prednisone, it significantly enhances radiographic progression-free survival (rPFS) compared to conventional hormonal therapy alone.
Which Companies Are Engaged In The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Environment?
Major companies operating in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.
Access The Complete Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Report:
Which Area Represents The Largest Portion Of The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=24495&type=smp
Browse Through More Reports Similar to the Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market 2026, By The Business Research Company
Prostate Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report
Urothelial Carcinoma Treatment Market Report 2026
Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
